Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Robert ChenAlex F HerreraJessie HouLu ChenJun WuYuming GuoTimothy W SynoldVu N NgoSandrine PuverelMatthew G MeiLeslie PopplewellShuhua YiJoo Y SongShu TaoXiwei WuWing C ChanStephen J FormanLarry W KwakSteven T RosenEdward M NewmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This study may provide a new therapeutic strategy to combat brentuximab vedotin resistance in Hodgkin lymphoma. This is the first study reporting an effect of multidrug resistance modulation on the therapeutic activity of an ADC in humans. The expansion phase of the trial is ongoing and enrolling patients who are refractory to brentuximab vedotin to confirm clinical activity in this population with unmet need.